Valtrovir tablets are indicated for:
Active substance: valaciclovir;
1 tablet contains valacyclovir hydrochloride in terms of valacyclovir - 500 mg;
Excipients: calcium stearate, sodium starch (type A), microcrystalline cellulose, coating mixture "Opadry II Yellow" 33G22623 (contains hypromellose; lactose monohydrate, titanium dioxide (E 171), polyethylene glycol 3000 (macrogol) triacetin; quinoline yellow ( E 104), sunset yellow FCF (E 110), iron oxide yellow (E172) indigo (E 132)).
Hypersensitivity to valacyclovir, acyclovir or to any other component of the preparation.
Treatment of herpes zoster: for adults, appoint 1000 mg (2 tablets) 3 times a day for 7 days.
Treatment of infections caused by the herpes simplex virus. Patients with normal immunity (adults): 500 mg (1 tablet) of the preparation 2 times a day.
Pregnant
Can be used only when the potential benefit of the treatment to the mother outweighs the potential risk to the fetus.
Children
It is used for children over 12 years of age for the prevention of cytomegalovirus infection and disease.
Drivers
Carefully.
Symptoms Overdose of valacyclovir has reported the development of acute renal failure and neurological symptoms, including confusion, hallucinations, agitation, decreased mental capacity and coma. Nausea and vomiting may have been observed. To prevent unintentional overdose, use caution. Many cases of overdose have been associated with the use of the preparation for the treatment of patients with renal insufficiency and elderly patients, for whom the dose has not been reduced accordingly.
Treatment. Patients need to be under close medical supervision to detect manifestations of toxicity. Hemodialysis significantly accelerates the elimination of acyclovir from the blood and therefore it can be considered the optimal treatment in case of symptomatic overdose.
Among the more serious adverse reactions were reports of thrombotic thrombocytopenic purpura / hemolytic uremic syndrome, acute renal failure, and neurological disorders.
No clinically significant forms of interaction were identified.
Patients who receive higher doses of the preparation (4 g or more per day) should be careful when prescribing with preparations that compete with acyclovir for the elimination route, as this can lead to an increase in plasma levels of one or both preparations and their metabolites ... With simultaneous use with mycophenolate mofetil (an immunosuppressive preparation used after organ transplant), the plasma level of acyclovir and the inactive metabolite of mycophenolate mofetil increases.
You should also be careful (with monitoring changes in renal function) while prescribing high doses of the preparation (4 g or more) and other preparations that affect renal function (for example, cyclosporine, tacrolimus).
Store in its original packaging at a temperature not exceeding 25 ° C.
Keep out of the reach of children.
Shelf life is 2 years.
There are no reviews for this product.